Repatha and Injection site macule - a phase IV clinical study of FDA data

Summary:

Injection site macule is reported as a side effect among people who take Repatha (evolocumab), especially for people who are male, 60+ old, also take Crestor, and have Lipoprotein (a) increased.

The phase IV clinical study analyzes which people have Injection site macule when taking Repatha. It is created by eHealthMe based on reports of 155,838 people who have side effects when taking Repatha from the FDA, and is updated regularly.

What is Repatha?

Repatha has active ingredients of evolocumab. It is often used in high blood cholesterol. eHealthMe is studying from 156,258 Repatha users. Check the latest studies of Repatha.

What is Injection site macule?

Injection site macule (alterations in skin colour at injection site) is found to be associated with 29 drugs and 93 conditions by eHealthMe. Check the latest studies of Injection site macule.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

155,838 people reported to have side effects when taking Repatha.
Among them, 26 people (0.02%) have Injection site macule.

Could Repatha cause Injection site macule?

Among these 26 people:

What is the gender of people who have Injection site macule when taking Repatha? *

female: 46.15 %
male: 53.85 %

What is the age of people who have Injection site macule when taking Repatha? *

What are other drugs people take besides Repatha? *

What are other side effects people have besides Injection site macule? *

Injection Site Pain: 9 people, 34.62%
Injection Site Erythema (redness at injection site): 8 people, 30.77%
Injection Site Bruising: 5 people, 19.23%
Influenza Like Illness: 4 people, 15.38%
Pain: 4 people, 15.38%
Injection Site Haemorrhage (bleeding from injection site): 4 people, 15.38%
Injection Site Pruritus (severe itching at injection site): 3 people, 11.54%
Headache (pain in head): 3 people, 11.54%
Injection Site Discoloration: 3 people, 11.54%
Back Pain: 3 people, 11.54%

What are the existing conditions these people have? *

Low Density Lipoprotein Increased (cholesterol increased in blood): 2 people, 7.69%
Lipoprotein (A) Increased (increased molecules made of proteins and fat): 2 people, 7.69%
Hyperlipidaemia (presence of excess lipids in the blood): 1 person, 3.85%

* Approximation only. Some reports may have incomplete information.

Do you take Repatha and have Injection site macule?

- Check whether Injection site macule is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Repatha:

Repatha (156,258 reports)

Browse all side effects of Repatha:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site macule:

Injection site macule (29 drugs)

Browse all the conditions that are associated with Injection site macule:

Injection site macule (93 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on evolocumab (the active ingredients of Repatha) and Repatha (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.